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T cells are central players in the regulation of adaptive im-
munity and immune tolerance. In the periphery, T cell differ-
entiation for maturation and effector function is regulated by 
a number of factors. Various factors such as antigens, 
co-stimulation signals, and cytokines regulate T cell differ-
entiation into functionally specialized effector and regulatory 
T cells. Other factors such as nutrients, micronutrients, nu-
clear hormones and microbial products provide important en-
vironmental cues for T cell differentiation. A mounting body 
of evidence indicates that the microbial metabolites short- 
chain fatty acids (SCFAs) have profound effects on T cells 
and directly and indirectly regulate their differentiation. We 
review the current status of our understanding of SCFA func-
tions in regulation of peripheral T cell activity and discuss 
their impact on tissue inflammation.
[Immune Network 2014;14(6):277-288]
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Commensal microbiota functions not only to serve as targets 
of host immunity but also as active players in regulation of 
host physiology and immunity as a result of long-term co-
evolution of the host and microbes. T cells play central roles 
in the regulation of anti-microbial immunity and tissue 
inflammation. Most major T cell types are made in the thy-
mus, although extrathymic generation of some T cell subsets 
has been described (1,2). T cells are divided into the major 
TCR-αβ and minor γδ T cell groups. αβ T cells are highly 
heterogeneous and grouped into CD4
＋
 conventional T cells, 
CD8
＋
 conventional T cells, NKT cells, and other innate TCRα- 
expressing T cells such as mucosal-associated invariant T 
(MAIT) cells (3-6). CD4
＋
 conventional T cells are further div-
ided into FoxP3
＋
 regulatory and FoxP3
−
 T cells (7,8). FoxP3
−
 
CD4＋ T cells include various effector and regulatory T cells 
based on their cytokine phenotype (IFNγ, IL-17, IL-22, IL-4, 
IL-9, IL-10, IL-35, and/or LAP-TGFβ1) (6,9). These T helper 
cells include IFNγ＋ Th1 cells, IL-17/IL-22＋ Th17 cells, IL-4＋ 
Th2 cells, IL-9
＋
 Th9 cells, IL-21
＋
 T-FH cells, and IL-10/IL-35/ 
TGFβ1
＋
 Tregs (9-12). All of these T helper cell subsets are 
generated mainly in the periphery from naïve T cells made 
in the thymus. TCR repertoire and antigen specificity/affinity 
greatly influence T cell differentiation in the thymus and pe-
riphery (13,14). Co-stimulation signals such as CD28, ICOS, 
CTLA4, OX-40, and PD-1 signaling reciprocally regulate T cell 
differentiation and effector function (15-17). Cytokine milieu 
during T cell activation is crucial to generate specialized effec-
tor versus regulatory T cell subsets (6,9). A mounting body 
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of evidence indicates that nutrients and metabolites provide 
significant regulatory signals for T cell differentiation (18-23). 
Potentially important roles of gut microbial products such as 
short-chain fatty acids (SCFAs) have been recently docu-
mented (24-26). In this review, we will review the recent 
progress in our understanding of the roles of SCFAs in regu-
lating CD4
＋
 T helper cell differentiation and the impact of 
this process on tissue inflammation.
ORIGIN, PRODUCTION, TRANSPORT, AND 
RECEPTORS OF SCFAs
SCFAs refer to free fatty acids containing fewer than 6 car-
bons and therefore they have short aliphatic carbon-chains. 
Formic acid (C1), acetic acid (C2), propionic acid (C3), buty-
ric acid (C4), and valeric acid (C5) belong to the SCFA group. 
These metabolites are distinguished from longer fatty acids 
such as medium-chain (6-12 carbons) and long-chain free fat-
ty acids. Because they have relatively shorter hydrophobic 
chains as well as the hydrophilic carboxyl group, SCFAs are 
water soluble and readily absorbed or transported into cells. 
SCFAs are produced by gut microbiota as fermentation prod-
ucts, meaning that they are partially oxidized from sugar mol-
ecules under anaerobic conditions in the colon. Carbohydra-
tes are good sources of SCFAs but SCFAs can be made from 
other nutrients such as proteins and peptides albeit at low 
levels (27). These SCFA precursors, however, are easily de-
graded by host digestive enzymes in the upper alimentary 
tract and don’t reach the microbiota in the colon in significant 
amounts for SCFA production. In contrast, digestion-resistant 
oligosaccharides and fibers (e.g. oligofructose, inulin, pectin, 
and arabinoxylan) are good sources of SCFAs. Insoluble fi-
bers including cellulose and chitin, however, are not readily 
fermented by the microbiota and thus do not produce SCFAs 
at significant levels.
  While it is yet to be determined clearly through extensive 
bacterial isolation and metagenomics studies, available in-
formation indicates that bacteria species greatly differ in their 
genetic make-up of enzymes involved in SCFA production 
(28,29). Among SCFAs, C2 is relatively more readily produced 
than C3 and C4 by most enteric and acetogenic bacteria (30). 
Propionate can be produced by three pathways (i.e. succi-
nate, acrylate, and propanediol) from various sugar molecules 
such as pentoses, hexoses, and rhamnose (31). Bacteroidetes 
and some Firmicutes are good producers of C3 mainly 
through the succinate pathway. Production of C4 requires ad-
ditional enzymatic processes that extend acetyl-CoA with bu-
tyryl-CoA:acetate CoA-transferase, which is active in some 
bacteria including Roseburia, Eubacterium and Anaerostipes 
species and Faecalibacterium prausnitzii (27,32).
  The combined concentrations of SCFAs produced in the co-
lon reach ∼150 mM, making SCFAs the most abundant 
anions in the colon. SCFAs are absorbed in the colon and 
either utilized in colonocytes or transported via the portal 
vein to reach the blood circulation and other organs. The liv-
er and muscle are major systemic organs for SCFA metabo-
lism and consumption. SCFAs enter cells through passive dif-
fusion and carrier-mediated transportation through SMCT1/ 
SLC5a8 and MCT1/SLC16a1 (33-35). SMCT1 is a sodium-cou-
pled monocarboxylate transporter 1 for cell intake of SCFAs 
and related organic acids such as lactate and pyruvate (34). 
SMCT1 belongs to the SLC5 Na
＋
/glucose cotransporter gene 
family (33). MCT1 is an H
＋
-coupled transporter for SCFAs 
and related organic acids and it transports these molecules 
depending on the net chemical gradients for H
＋
 and mono-
carboxylates across the membrane (36). Expression of these 
transporters in the apical membrane of colonocytes, DCs, kid-
ney cells, and/or brain cells has been documented (Table I).
  SCFAs activate several G-protein-coupled cell surface re-
ceptors (GPCR). GPR41 and GPR43 are major receptors that 
can be activated by most SCFAs (37). Gut enteroendocrine 
cells highly express GPR41 and GPR43 (38,39). Other regular 
enterocytes express these receptors also at functional levels 
(38-41). GPR41 is also expressed in adipocytes, renal smooth 
muscle cells, enteric neuronal cells, and pancreatic cells 
(Table I) (42,43). The expression of GPR41 is co-regulated 
with GPR40, a receptor for medium and long-chain fatty 
acids, because their gene transcription is regulated by the 
same promoter (44). GPR43 is expressed by granulocytes and 
some myeloid cells (45-47). GPR109a, a receptor for niacin 
(also called nicotinic acid and vitamin B3), is a receptor also 
for C4 (48). GPR109a is expressed by gut epithelial cells, adi-
pocytes, macrophages and dendritic cells (Table I). Olfr78 is 
expressed in the kidney juxtaglomerular apparatus and is acti-
vated by C2 and C3 (49). However, T cells do not express 
these receptors at functionally significant levels (unpublished 
results) (24). Major cell types expressing these receptors are 
listed in Table I.
BASIC FUNCTIONS OF SCFAs IN THE BODY
SCFAs, also called volatile fatty acids because of their rela-
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Table I. Expression of SCFA transporters and cell surface receptors
Transporter/ 
receptor Cell types Known functions References
MCT1 (SLC16a1) Colonic epithelial cells A H＋-coupled transporter for SCFAs and related 
organic acids
(107-109)
SMCT1 (SLC5a8) Apical membrane of colonocytes, dendritic 
cells, kidney, retina, and brain
A Na(＋)-coupled transport of monocarboxylates 
and ketone bodies into various cell types 
(34, 86, 
110-115)
GPR41 (FFAR3) Enteroendocrine, enteroneuronal cells, 
sympathetic ganglia, adipocytes, 
pancreas, renal smooth muscle cells
A receptor for SCFAs. Regulation of gut hormone, 
leptin production, and sympathetic activation, 
Epithelial innate immunity
(39, 40, 42, 44, 
46, 72)
GPR43 (FFAR2) Enteroendocrine L cells, adipocytes, gut 
epithelial cells, leukocytes (eosinophils, 
basophils, neutrophils, monocytes, 
dendritic cells), mucosal mast cells, 
vascular endothelium in the myometrium
A receptor for SCFAs. Secretion of PYY and 
GLP-1, adipocyte development, adipogenesis, 
suppression of lipolysis, epithelial innate 
immunity, antitumor activity, anti-inflammatory 
effect, and Treg differentiation





Adipocytes, dendritic cells, intestinal 
epithelial cells, macrophages, 
hepatocytes, epidermis in squamous 
carcinoma
A receptor for C4 and niacin. cAMP regulation, 
suppression of adipocyte lipolysis, HDL 
metabolism, DC trafficking, antitumor activity, 





Large renal vessels, renal afferent arterioles, 
extrarenal vascular beds, prostate cancer, 
cells of the autonomic nervous system
A receptor for C2 and C3. Renin production from 
kidney juxtaglomerular apparatus for regulation 
of blood pressure
(49, 127, 128)
tively more volatile nature compared to longer fatty acids, 
have been studied for more than a century (50,51). These 
early observations linked SCFAs to diarrhea and ion balance 
in the intestine. SCFAs are physiologically important in the 
intestine as they regulate ion absorption and gut motility. 
Because SCFAs are absorbed first into colonic epithelial cells 
and can be metabolized in these cells, they profoundly affect 
the basic biology of intestinal epithelial cells. SCFAs, partic-
ularly C4, are used as the major energy source for colonic 
epithelial cells and regulate their gene expression, pro-
liferation, differentiation, and apoptosis (52). For example, 
SCFAs promote the production of mucin and gastrointestinal 
peptide (e.g. LL-37) (53), molecules important for gut barrier 
function.
  SCFAs condition intestinal epithelial cells to make them 
more readily respond to bacterial products (40). This function 
is important to prepare epithelial cells for mounting optimal 
innate immune responses to invading pathogens and com-
mensal bacteria, and therefore helps prevent chronic in-
testinal inflammatory responses to microbes and their 
products. In this regard, SCFAs have anti-inflammatory activ-
ity in regulating intestinal inflammation (54). Intestinal epi-
thelial cells express GPR41, GPR43, and GPR109a, which me-
diate a significant portion of the SCFA function (48,55-57). 
These GPCRs activate signaling processes such as RAS, pro-
tein kinase A, PI3K, and ERK1/2 for activation of transcription 
factors such as ATF2 (40,47,48,58,59). Activation of this path-
way is important for expression of key immune and in-
flammatory mediators such as IL-1, IL-6, TNF-α, CXCL1, and 
CXCL2. Another function of SCFAs is to activate GPR41 and 
GPR43 on secretory epithelial cells to produce glucagon-like 
peptide (GLP)-1 (60). Enteric neurons express GPR41 to 
sense SCFAs for regulation of gut motility (39). To support 
this, there is a high correlation in expression sites between 
SCFA receptors and gut endocrine hormones such as GLP-1, 
PYY, and neurotensin. Another major mechanism for the 
SCFA regulation of epithelial cells is mediated through in-
hibition of HDACs by SCFAs (61,62).
  Other cell types are also regulated by SCFAs. SCFAs induce 
the chemotaxis of neutrophils via activation of GPR43 (58,59) 
and regulate neutrophil degranulation (63,64). SCFAs also 
regulate macrophages and dendritic cells (DCs) (65,66).  
SCFAs suppresses NF-kB and the production of inflammatory 
cytokines such as IL-6 and TNF-α but increases IL-10 secre-
tion from macrophages (67). In contrast, increased C2 levels 
in alcoholism can increase the expression of inflammatory cy-
tokines in macrophages and even exacerbate the in-
flammatory response in the liver (68). Thus, the SCFA func-
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Figure 1. Regulation of T cells by SCFAs. SCFAs are actively produced 
by anaerobic microbiota in the colon as fermentation products of 
dietary materials. Most carbohydrates and proteins are completely 
digested and absorbed in the stomach and small intestine, and don’t
efficiently make SCFAs. SCFAs are mainly produced from digestion- 
resistant dietary fibers that reach the colon to be processed by the 
microbiota. SCFAs are absorbed or transported into colonocytes. They 
are metabolized in colonocytes or transported into blood circulation 
to reach other organs such as the liver and muscles. SCFAs exert their 
regulatory effects on epithelial cells, antigen presenting cells and T 
cells. Multiple mechanisms are involved including metabolic 
regulation, HDAC inhibition, and GPCR activation by SCFAs. These 
activation signals are combined to regulate T cell differentiation 
directly or indirectly. The direct effect of SCFAs on T cells enhances 
the generation of Th1 and Th17 cells in appropriate cytokine 
conditions, which is important to boost immunity to fight pathogens. 
SCFAs efficiently promote T cell production of IL-10, which is 
important to prevent inflammatory responses. It has been reported 
that SCFAs can expand FoxP3＋ T cells in certain activation 
conditions. SCFAs may exert their regulatory effects on developing 
DCs to generate DCs that are limited in their ability to present 
antigens and cytokines to make effector T cells. These effects are 
combined to create the overall tolerogenic gut environment with a 
strong barrier function.
tion in regulation of immune responses may be altered in 
pathological conditions. SCFAs increase satiety and recip-
rocally regulate adipogenesis and lipolysis (69-71). 
Adipocytes express GPR41 and are activated by SCFAs to pro-
duce leptin (42,43,72). Olfr78 activation promotes renin pro-
duction from the kidney to regulate blood pressure (49).
COMPLEX ROLES OF SCFAs IN REGULATION OF 
EFFECTOR VERSUS REGULATORY T CELLS
Early work on C4 revealed its regulatory effect on cytokine 
production by lymphocytes (73,74). C4 had regulatory effects 
on production of cytokines such as IL-2, IL-4, IL-5, IL-6, and 
IL-10 (75). Others observed that C4 induced Fas-upregulation 
and apoptosis in T cells (76). Smith et al. reported that mice 
fed with SCFAs had increased numbers of IL-10-producing 
FoxP3
＋
 T cells in the colon (25). The effect was specific for 
colonic FoxP3＋ T cells, and FoxP3＋ T cells in other organs 
were not expanded after SCFA administration. A mechanism 
provided by this group for the expanded colonic FoxP3
＋
 T 
cells was decreased HDAC expression and activity by SCFAs 
in a GPR43-depednent manner. SCFAs can enter cells through 
diffusion or carrier-mediated transport and thus do not neces-
sarily go through cell surface receptors. Moreover, T cells do 
not express GPR43 at significant levels and thus this mecha-
nism remains to be verified. Another group reported that C2 
and C3 can directly suppress HDACs and increase histone 
acetylation at the FoxP3 gene locus for increased transcription 
(20). Similarly, it was reported that Treg generation was in-
creased by SCFAs as a result of HDAC inhibition by SCFAs 
and histone H3 acetylation in key regulatory regions of the 
Foxp3 locus (77). In relation to these reports, inoculation of 
germ-free mice with SCFA-producing Clostridia groups in-
duced IL-10 and ICOS-expressing FoxP3
＋
 T cells (78). 
Overall, these studies suggest that SCFAs expand colonic 
Tregs for immune tolerance.
  Our group found that SCFAs can increase IL-10, but not 
necessarily FoxP3, expression in T cells (24). Interestingly, 
SCFA either positively or negatively regulate induced FoxP3＋ 
cells depending on the strength of T cell activation in vitro. 
In high T cell activation conditions, SCFAs can even suppress 
FoxP3＋ cell induction promoted by TGFβ1 and T cell 
activation. In contrast, SCFAs enhance FoxP3
＋
 cell induction 
at low T cell activation conditions. Independent of FoxP3 reg-
ulation, SCFAs increased IL-10 production in all T cell activa-
tion conditions (24). We observed that the FoxP3
＋
 T cells 
even in the colon were not reproducibly regulated by SCFA 
administration in vivo (unpublished results). These results im-
ply that FoxP3 induction by SCFAs may be regulated by in-
direct mechanisms through non-T cells. A rather surprising 
finding was that SCFAs facilitated naïve T cell differentiation 
into Th1 and Th17 cells in appropriate T cell polarization 
conditions. Thus, SCFAs can enhance both effector and regu-
latory T cells depending on the immunological milieu. In sup-
port of this, C2 administration via drinking water increased 
Th1 and Th17 cells in the intestine and secondary lymphoid 
tissues during C. rodentium infection (40). In the absence of 
infection, SCFAs increased gut IL-10＋ T cells in vivo, which 
would promote immune tolerance. It appears that SCFAs se-
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lectively promote only the right types of T cells required to 
handle specific immunological conditions (Fig. 1).
POTENTIAL MECHANISMS FOR THE REGULATORY 
EFFECT OF SCFAs ON T CELLS
Cells can be regulated by SCFAs largely in three different 
mechanisms (Fig. 1). The first mechanism involves the activa-
tion of SCFA-binding G-protein-coupled receptors (GPCRs) 
such as GPR41, GPR43, GPR109A, and Olfr78. GPCR signaling 
can regulate cell activation, proliferation, and differentiation. 
However, T cells do not express any of these receptors at 
significant levels, according to published information and un-
published microarray data. Thus, SCFA receptors are not like-
ly to be important for direct regulation of T cells by SCFAs. 
Another pathway is to regulate cell energy status and relevant 
signaling processes through integration of SCFAs into cellular 
metabolism. SCFAs can be converted to Acetyl-CoA and in-
tegrated into the citric acid cycle (Krebs cycle). Acetyl-CoA 
is a central molecule that stores energy in the molecule, 
which is eventually oxidized to CO2 for energy production. 
As the result, the cellular energy [ATP/ADP] level increases, 
and this change boosts mTOR activation (79). In T cells, acti-
vation of mTOR skews T cell differentiation into effector T 
cells such as Th1 and Th17 cells at the expense of FoxP3
＋
 
T cells (80). mTOR activation also promotes the generation 
of IL-10＋ cells (81). Thus, the SCFA-regulation of cell metabo-
lism and mTOR accounts for the increased generation of Th1, 
Th17 cells, and IL-10
＋
 cells. The third mechanism is mediated 
through the HDAC inhibitor activity of SCFAs (Fig. 1). All ma-
jor SCFAs such as C2, C3, C4 and C5 have HDAC inhibitor 
activity (24,82,83). Some regarded that C2 does not have the 
HDAC inhibitor activity but it has clear HDAC inhibitor activ-
ity at concentrations (∼10 mM) higher than C3 and C4 (∼1 
mM) (24). Moreover, C2 is maintained at relatively high con-
centrations in blood (∼1 mM). This HDAC inhibitor activity 
requires the transport of SCFAs into cells and enzymatic in-
hibition of HDACs. Class I/II HDACs are major targets of 
SCFA inhibition. While SCFAs do not suppress class III HDAC 
such as Sirt1, down-regulation of Sirt1 expression by SCFAs 
was reported (84). Thus, SCFAs may affect a broad range of 
HDACs for their regulatory effects. Because HDAC inhibition 
increases the acetylation of histone and other proteins, the 
impact of this activity is far reaching and affecting a number 
of genes and proteins. Physical interaction between HDACs 
and S6K has been reported (85), and S6K is a downstream 
effector molecule of the mTOR pathway. P70-S6 Kinase 1 
(S6K) is hyper-acetylated by SCFAs in T cells, leading to in-
creased mTOR activity in T cells (24).
  SCFAs can indirectly affect T cells through their effects on 
other cells that control T cell differentiation such as DCs (Fig. 
1). SCFAs suppress the development of bone marrow progen-
itors into myeloid DCs in vitro (86). It has been observed 
that SCFAs also inhibit functional maturation of DCs in vitro 
(66,86-90). For example, C4 suppressed the maturation of 
bone marrow-derived DCs and production of IL-12 but in-
creased the expression of IL-23p19 (89). Valproic acid, a 
branched short-chain fatty acid and potent HDAC inhibitor, 
suppressed the maturation of human DCs in vitro, inhibiting 
the up-regulation of T-cell activating molecules such as MHC 
II, CD80, CD86 and IL-12 (90). While the functional im-
portance is yet to be determined, a report indicates that C4 
increased CD1d at the expense of CD1a expression on devel-
oping human DCs (88). GPR109a activation affects colonic 
macrophages and DCs for generation of Tregs and IL-10-pro-
ducing T cells (91). This effect, however, is not solely due 
to C4, because GPR109a is a receptor for niacin as well. In 
this regard, niacin treatment suppressed colitis and colon can-
cer in a Gpr109a-dependent manner. Moreover, Gpr109a
−/−
 
colonic epithelial cells were defective in producing IL-18 in 
response to C4. More studies are required to separate the nia-
cin from SCFA effect in regulation of GPR109a. Overall, the 
published results indicate that the regulatory effects of SCFAs 
have the potential to steer DC development into tolerogenic 
DCs for promotion of immune tolerance. A caveat is that it 
remains to be fully determined if SCFAs would exert the same 
inhibitory effect on DCs in vivo.
REGULATION OF TISSUE INFLAMMATION BY SCFAs
The intestine is the first organ that encounters gut commensal 
bacteria-derived SCFAs. Therefore, SCFAs have been studied 
for decades for their effects on inflammatory bowel diseases 
(IBD). Despite some conflicting reports, high SCFA-producing 
conditions formed with high levels of dietary fibers are linked 
to decreased tissue inflammation in the intestine (92-94). Oral 
administration of C4 ameliorated T cell-induced colitis in lym-
phopenic mice (26). C4 administration attenuated inflam-
mation and mucosal lesions in dextran sodium sulfate (DSS)- 
induced colitis, an experimental model frequently used for ul-
cerative colitis (95). However, there is a conflicting report that 
C4 administration via drinking water worsened the colitis in-
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Figure 2. Regulation of tissue inflammation by SCFAs. SCFAs have 
the potential to regulate tissue inflammation through their effects on 
multiple cell types. The first cell type that is regulated by SCFAs is 
intestinal epithelial cells. SCFAs condition these cells to produce 
immune mediators that enhance the gut barrier function. Also, the 
response to pathogens and commensal bacteria is heightened by 
SCFAs during inflammatory responses. The next cell type that is 
affected is antigen presenting cells. SCFAs act on DCs to limit the 
expression of T cell-activating molecules such as MHC II molecules, 
co-stimulatory molecules, CCR7 and cytokines, leading to generation 
of tolerogenic T cells rather than inflammatory T cells. The tolero-
genic effect of SCFAs on DCs can lower inflammatory responses. 
SCFAs can directly affect naïve T cells to steer their differentiation 
into both effector and IL-10-producing T cells. Moreover, SCFAs 
attract neutrophils to the gut during immune responses. Together, the 
enhanced barrier function, T cell immunity, and neutrophil recruit-
ment help prevent infection by pathogens and invasion by com-
mensal bacteria. By the same token, the activating activity of SCFAs 
for the immune cells and epithelial cells may boost inflammatory 
responses, if not properly regulated.
duced by DSS (89). SCFAs also failed to regulate the acute 
colitis induced with 2,4,6-Trinitrobenzenesulfonic acid (TNBS) 
(96). These conflicting results may have been obtained due 
to differences in methods to induce inflammation and regi-
mens to treat the heterogeneous inflammation. To make the 
function of SCFAs even more complicated, both increased 
and decreased DSS-induced inflammation in GPR43-deficient 
mice has been reported (45,97). GPR43-deficient mice had 
exacerbated inflammation in animal models of colitis, arthritis 
and asthma (97). GPR43 may modulate gut inflammation, in 
part, through cytokine production by mononuclear cells (98). 
GPR43 and GPR41, expressed by tissue cells such as epithelial 
cells, are also important to prevent chronic inflammation in 
the intestine following C. rodentium infection (40). Thus, the 
available information suggests that SCFA receptors play an 
overall beneficial role in prevention of inflammation (Fig. 2). 
More work is required to identify the cell types and mecha-
nisms that mediate the beneficial effect of SCFAs in a SCFA 
receptor-dependent manner.
  In humans, C4 enemas had a small ameliorating effect on 
human colitis patients (99). Treatment of patients with distal 
ulcerative colitis with C4 (100 mM) was effective in ameliorat-
ing disease activity (100). Moreover, treatment of patients 
with mild to moderate distal ulcerative colitis with combined 
SCFA enemas (100 mL, twice daily enemas of sodium acetate 
80 mM, sodium propionate 30 mM, and sodium butyrate 40 
mM) were effective in ameliorating colitis (101). A similar 
therapeutic effect was observed in ∼50% of ulcerative colitis 
patients who were refractory to a rectal and oral therapy with 
5-aminosalicylic acid and corticosteroid (101). SCFAs im-
proved the efficacy of other treatments such as oral mesala-
zine therapy (102). There is a report that patients with mild 
to moderate ileocolonic Crohn's disease who were treated 
with 4 g/day C4 tablets for 8 weeks had decreased clinical 
activity (103). A caveat is that several large randomized stud-
ies found no significant effects of SCFA therapies on ulcer-
ative colitis patients (104,105). These mixed results indicate 
that SCFAs and their receptors may regulate inflammatory re-
sponses only in certain pathological conditions, ameliorating 
certain types of inflammatory responses while exacerbating 
other types of responses. Beyond inflammatory bowel dis-
eases, high fiber diets and SCFAs have suppressive effects on 
respiratory allergic diseases (106). Overall, SCFAs have the 
potential to work through multiple cell types, including T 
cells, to exert their regulatory effects on tissue inflammation 
(Fig. 2).
CONCLUDING REMARKS
The gut microbial metabolites SCFAs profoundly regulate T 
cell differentiation in the body. Because these metabolites are 
produced at high levels in the gut, the T cells in the intestine 
and gut-associated lymphoid tissues are an important cell tar-
get for regulation by SCFAs. SCFAs can be transported into 
the blood and have the potential to regulate T cell activity 
in systemic tissue sites as well. Beyond T cells, SCFAs regu-
late the function and phenotype of a number of immunologi-
cally important cell types such as epithelial cells, neutrophils, 
and antigen presenting cells. While the anti-inflammatory ac-
tivity of SCFAs has been emphasized, SCFAs can also promote 
the generation of effector T cells and enhance gut barrier 
function and innate immunity. All of these effects of SCFAs 
are important to maintain a healthy immune system and to 
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prevent inflammatory diseases. More studies are required to 
sort out the detailed mechanism of SCFA-mediated regulation 
of T cells and other immune cells. The current body of liter-
ature indicates that SCFAs are not a panacea for inflammatory 
diseases and may exacerbate certain types of tissue 
inflammation. Therefore, it is important to identify the types 
of cells, immune responses, tissue inflammation, and diseases 
that are highly responsive to SCFA-based therapies. 
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